In the past two months alone, Wall Street investors have pumped billions into a handful of biotech companies in the early stages of producing vaccines or drugs to combat the novel coronavirus. Some of these companies are pursuing promising treatments, experts say, but others are likely to strike out on finding a cure. The result: a coronavirus investment bubble that's already approaching nearly $200 billion in stock market value.